Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) Gross Profit (2023 - 2025)

ImmunityBio (IBRX) has disclosed Gross Profit for 3 consecutive years, with $37.9 million as the latest value for Q4 2025.

  • Quarterly Gross Profit rose 401.89% to $37.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $112.5 million through Dec 2025, up 663.21% year-over-year, with the annual reading at $112.5 million for FY2025, 663.21% up from the prior year.
  • Gross Profit for Q4 2025 was $37.9 million at ImmunityBio, up from $31.9 million in the prior quarter.
  • The five-year high for Gross Profit was $37.9 million in Q4 2025, with the low at $40000.0 in Q1 2024.
  • Average Gross Profit over 3 years is $11.6 million, with a median of $6.1 million recorded in 2024.
  • Peak annual rise in Gross Profit hit 41047.5% in 2025, while the deepest fall reached 401.89% in 2025.
  • Over 3 years, Gross Profit stood at $139000.0 in 2023, then surged by 5333.09% to $7.6 million in 2024, then surged by 401.89% to $37.9 million in 2025.
  • According to Business Quant data, Gross Profit over the past three periods came in at $37.9 million, $31.9 million, and $26.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.